Quantum-Biosciences LLC, a start-up company formed with the mission of development and commercialization of Cethromycin/QB101 for malaria prophylaxis, announces changes in its structure to a C-corp and its name to AliquantumRx Inc. David Sullivan, MD, professor of molecular microbiology and immunology at the Johns Hopkins Malaria Research Institute, the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins Center for Global Health joins Nikola Kaludov, PhD, managing member of Quantum-Biosciences LLC as a co-founder of AliquantumRx Inc. Dr. Sullivan becomes the Chair of the Board and Dr. Kaludov becomes the President of the new company. The new company is registered in Maryland and is a client of Fast Forward, an accelerator at Johns Hopkins.
“I am very excited that David decided to become a co-founder of Aliquantum” said Dr. Kaludov. “We have worked together towards discovery of novel antimalarials since 2011. He brings over 20 years of experience on all aspects of malaria research, particularly field studies in endemic regions, drugs and diagnostics and has published over 100 malaria papers. In addition, the new corporate structure will make it easier to license intellectual property and attract investors to further develop cethromycin as a novel antimalarial drug.”
